Linklaters advises on HUTCHMED’s HK$4.17bn HKEX IPO

Linklaters advised the joint sponsors and underwriters on the global offering and listing of HUTCHMED (China) Limited (HUTCHMED) on the main board of the Hong Kong Stock Exchange (Stock Code: 13).

HUTCHMED, formerly known as Chi-Med (Hutchison China MediTech), is part of the multinational conglomerate CK Hutchison group. It is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialisation of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. It is the first biotech company to bring a novel oncology drug from discovery through to unconditional approval and launch in China.

Upon listing on the Hong Kong Stock Exchange today, HUTCHMED has now become triple primary listed with its American Depositary Shares (ADSs) listed on the Nasdaq Global Select Market and its shares also listed on the AIM of the London Stock Exchange. HUTCHMED continues to evaluate the possibility of seeking further listings on other stock exchanges such as the Shanghai Stock Exchange Science and Technology Innovation Board.

The Linklaters team was led by corporate partners Kevin Cheung and Christopher Yip, with support from managing associates Tiffany Yan and Chloe Choy.

Partner, Christopher Yip, commented:

“Our involvement in this successful listing not only consolidates our firm’s long-standing reputation in the equity space, but also reflects our expertise in the biotech and healthcare sector. We are committed to supporting the development of life sciences companies at every stage.”